All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub is pleased to present a visual abstract highlighting key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Updates are focused on the increased separation between AML types defined by genetic abnormalities and those defined by differentiation, while still recognizing the impact and integration of clinical, molecular/genetic, and pathological factors.
To download this visual abstract, click below.Download here
AML World Awareness Day 2020 | The value of measurable residual disease in acute myeloid leukemia
Although up to 80% of patients with AML achieve morphologic complete remission (mCR) following induction therapy, disease recurrence is common—with...
Serum miR-223 expression in patients with acute myeloid leukemia
MicroRNAs (miRNAs) are single stranded, small, non-coding RNAs which are known to play an important role in many biological processes and are detectable in serum and plasma samples....
Subscribe to get the best content related to AML delivered to your inbox